Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of MBP polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Guinea pig,Human,Rat |
| Host species | Rabbit |
| Applications | IHC |
More info about MBP polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB14324 |
| Product name: | MBP polyclonal antibody |
| Product description: | Rabbit polyclonal antibody raised against synthetic peptide of MBP. |
| Immunogen: | A synthetic peptide (conjugated with KLH) corresponding to amino acids 68-86 of guinea pig MBP. |
| Immunogen sequence/protein sequence: | YGSLPQKSQRSQDENPVV |
| Protein accession: | P25188 |
| Form: | Lyophilized |
| Recommend dilutions: | Immunohistochemistry (1:1000-1:4000) The optimal working dilution should be determined by the end user. |
| Storage buffer: | Lyophilized from PBS |
| Storage instruction: | Store at 4°C on dry atmosphere. After reconstitution with deionized water, store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Product type: | Primary antibodies |
| Host species: | Rabbit |
| Antigen species / target species: | Guinea pig |
| Specificity: | This antiserum recognizes MBP in demyelinated nerve tissues. Immunohistochemical analysis of lesioned rat spinal cord indictaes a high level of specificity for this antiserum. |
| Reactivity: | Guinea pig,Human,Rat |
| Application image: |  |
| Application image note: | Immunohistochemistry on human brain with brain trauma (car accident), using MBP polyclonal antibody (Cat # PAB14324) at a dilution of 1 : 2000. Courtesy of Dr. Wei-Ping Gai, The Flinders University of South Australia. |
| Applications: | IHC |
| Shipping condition: | Dry Ice |
| Publications: | Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease.Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, Smirnov I, Steinman L, Schwartz M. J Clin Invest. 2001 Aug;108(4):591-9. |